Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (IMAB), now NovaBridge Biosciences, reports biotechnology developments tied to precision immuno-oncology drug development for cancer. Its recurring updates center on givastomig, a Claudin 18.2 x 4-1BB bispecific antibody designed for Claudin 18.2-positive gastric cancers and other gastrointestinal tumors, and on ragistomig, a PD-L1/4-1BB bispecific antibody being developed with ABL Bio for solid tumors.
Company updates also cover clinical data presentations, trial-program activity, operating and financial results, shareholder voting matters, capital-structure disclosures, board composition, committee formation, and the completed transition from I-Mab to NovaBridge Biosciences, including the Nasdaq ADS ticker change.
I-Mab (Nasdaq: IMAB) announced the dosing of the first patient in a Phase 1b clinical trial for plonmarlimab (TJM2), targeting rheumatoid arthritis (RA) in China. This multi-center, double-blind, placebo-controlled study will involve 63 patients over eight weeks, assessing safety and efficacy. Plonmarlimab, a humanized IgG1 antibody, neutralizes GM-CSF to potentially reduce inflammation in RA. The company aims to establish proof of concept for RA and plans to explore broader autoimmune applications, marking a significant step in its pipeline development.
I-Mab (Nasdaq: IMAB) announced it will report financial results for the six months ended June 30, 2020, before the market opens on August 31, 2020. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss these results and provide a corporate update. I-Mab, a clinical-stage biopharmaceutical company, focuses on developing novel biologics for immuno-oncology and autoimmune diseases, aiming to bring transformational medicines to patients through innovation. The company's innovative pipeline includes over 10 drug candidates at various stages.
I-Mab (Nasdaq: IMAB) announced the acceptance of its pivotal trial application for eftansomatropin (TJ101) by the China National Medical Products Administration. This innovative long-acting recombinant human growth hormone aims to treat pediatric growth hormone deficiency (PGHD). The Phase 3 trial will enroll approximately 165 subjects, comparing eftansomatropin with the daily treatment Norditropin. Preliminary trials indicate that eftansomatropin is well-tolerated and effective, addressing a significant unmet medical need in China, where PGHD affects around 3.4 million patients.
I-Mab (Nasdaq: IMAB) announced the appointment of Ivan Yifei Zhu as Chief Commercial Officer, effective August 10, 2020. Zhu aims to enhance I-Mab's commercialization strategies and infrastructure, preparing for impending product launches. With over 20 years of experience in global and domestic pharmaceutical firms, he has successfully led product launches, including China's first domestic biosimilar of bevacizumab. This appointment marks a significant step for I-Mab, as the company transitions towards becoming a fully integrated global biopharmaceutical entity.
I-Mab (Nasdaq: IMAB) has authorized a stock repurchase program of up to US$20 million for its ordinary shares. This initiative reflects the company's confidence in its pipeline and commitment to enhancing long-term shareholder value. The buyback will be subject to market conditions and executed in accordance with regulatory guidelines. Repurchases can be made over the next 12 months, depending on various factors, including market pricing and capital availability.
Summary not available.
Summary not available.